PulmoBiomed
PulmoBioMed is a pioneering medical technology company focused on developing non-invasive, breath-based diagnostic devices for lung health. Their flagship product, PBM-Hale™, is a deep lung fluid collector that enables rapid, contamination-free sampling of aerosols, gases, and volatile organic compounds from the small airways, aiding in the diagnosis and stratification of lung conditions such as asthma, COPD, and respiratory infections. The company is committed to transforming respiratory medicine through innovative, science-backed solutions, with a mission to improve diagnostic accuracy and patient outcomes.
Industries
Nr. of Employees
small (1-50)
PulmoBiomed
Drayman’s Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX
Patents
Products
Hand-held non-invasive deep lung fluid collector (exhaled breath condensate sampler)
A hand-held clinical sampling device and associated disposable consumables that condenses and collects aerosols, gases and VOCs from the distal lung for downstream molecular and protein analyses.
Hand-held non-invasive deep lung fluid collector (exhaled breath condensate sampler)
A hand-held clinical sampling device and associated disposable consumables that condenses and collects aerosols, gases and VOCs from the distal lung for downstream molecular and protein analyses.
Services
Provision of disposable separators and sealed sampling vials designed for reproducible non-invasive collection of distal lung condensate and aerosols for research and clinical use.
Partnerships with clinical research groups and pharmaceutical sponsors to run sample collection protocols, support trial sampling logistics, and supply devices for patient stratification studies.
Provision of device instructions for use (IFU), technical support for sampling protocols, and access to supporting peer-reviewed and conference literature documenting sampling performance.
Provision of disposable separators and sealed sampling vials designed for reproducible non-invasive collection of distal lung condensate and aerosols for research and clinical use.
Partnerships with clinical research groups and pharmaceutical sponsors to run sample collection protocols, support trial sampling logistics, and supply devices for patient stratification studies.
Provision of device instructions for use (IFU), technical support for sampling protocols, and access to supporting peer-reviewed and conference literature documenting sampling performance.
Expertise Areas
- Breath-based sampling and diagnostics
- Clinical sample collection for respiratory research
- Multi-omic biomarker sampling (RNA, protein, microbiome)
- Respiratory infectious disease detection from exhaled aerosols
Key Technologies
- Exhaled breath condensate sampling
- Breath aerosol fractionation
- Aerosol particle capture and condensation
- PCR-based pathogen detection
News & Updates
PulmoBioMed completes Seed Investment Round
The company raised £1.45 million from US, EU, and UK investors to scale manufacturing and enter the US market with PBM-Hale™.
First Top 10 Pharma study starts
A European clinical research group will evaluate if PBM-HALE samples can predict treatment response in severe eosinophilic asthma.
PulmoBioMed team attends the annual ESCMID conference in Barcelona
The team showcased the non-invasive collection of airway fluids and met with collaborators, including new Principal Scientist Dr. Michelle Sugimoto.
Revolutionary breathe-based diagnostic technology allows for non invasive 'deep lung fluid' sampling
The company developed a technology that improves diagnostic time and accuracy for lung conditions, supported by funding from Innovation SuperNetwork.
PulmoBioMed wins the BioNOW BioCap pitching competition
Recognized as one of the most innovative UK medtech/biotech SMEs.
100% detection of symptomatic COVID-19, with just 1 min of breath
Preliminary data shows PBM-HALE can detect SARS-CoV-2 RNA in exhaled aerosols with 100% accuracy in symptomatic patients.
PulmoBioMed completes Seed Investment Round
The company raised £1.45 million from US, EU, and UK investors to scale manufacturing and enter the US market with PBM-Hale™.
First Top 10 Pharma study starts
A European clinical research group will evaluate if PBM-HALE samples can predict treatment response in severe eosinophilic asthma.
PulmoBioMed team attends the annual ESCMID conference in Barcelona
The team showcased the non-invasive collection of airway fluids and met with collaborators, including new Principal Scientist Dr. Michelle Sugimoto.
Revolutionary breathe-based diagnostic technology allows for non invasive 'deep lung fluid' sampling
The company developed a technology that improves diagnostic time and accuracy for lung conditions, supported by funding from Innovation SuperNetwork.
PulmoBioMed wins the BioNOW BioCap pitching competition
Recognized as one of the most innovative UK medtech/biotech SMEs.
100% detection of symptomatic COVID-19, with just 1 min of breath
Preliminary data shows PBM-HALE can detect SARS-CoV-2 RNA in exhaled aerosols with 100% accuracy in symptomatic patients.